Tyra Biosciences, Inc. Common Stock (TYRA) is a publicly traded Healthcare sector company. As of May 21, 2026, TYRA trades at $34.00 with a market cap of $2.12B and a P/E ratio of -16.75. TYRA moved -1.04% today. Year to date, TYRA is +27.04%; over the trailing twelve months it is +234.67%. Its 52-week range spans $6.42 to $40.65. Analyst consensus is strong buy with an average price target of $50.30. Rallies surfaces TYRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Tyra Biosciences Holds $383.5M Cash, Doses First Patient in SURF303: Tyra Biosciences held $383.5 million in cash and marketable securities at Q1 2026, extending its operational runway into H2 2028. The company dosed its first patient in the Phase 2 SURF303 LG-UTUC study and expects SURF302 Phase 2 data in August and BEACH301 results in Q4.
| Metric | Value |
|---|---|
| Price | $34.00 |
| Market Cap | $2.12B |
| P/E Ratio | -16.75 |
| EPS | $-2.01 |
| Dividend Yield | 0.00% |
| 52-Week High | $40.65 |
| 52-Week Low | $6.42 |
| Volume | 150 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-119.95M |
| Gross Margin | 0.00% |
13 analysts cover TYRA: 0 strong buy, 13 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $50.30.